Most comprehensive survey of women with ovarian cancer ever undertaken suggests raising awareness of the disease could improve outcomes for women.
A global study of women with ovarian cancer has found that two thirds of women had never heard of … Read more
Cancer patients could be spared unnecessary chemotherapy – and its side effects – by a new blood test that is in clinical trials at more than 40 hospitals in Australia and New Zealand.
The trials, led by Melbourne researchers, are … Read more
Ovarian tumors disable the immune system’s killer T cells—which protect the body by destroying infected or malignant cells—enabling the disease to flourish unchecked, according to a new study by Weill Cornell Medicine scientists. The findings show that adverse conditions within … Read more
The Clearity Foundation held its Teal Woman 10th Anniversary Celebration on September 16, 2018, at the Paradise Point Resort. The event, themed, “Teal Woman: Celebrating Life. Honoring Courage. Recognizing Progress. Changing the Story for Ovarian Cancer,” helped us to shine … Read more
New research from the University of Illinois at Chicago shows that cancer cells in the fallopian tube affect normal chemical signaling between reproductive tissues and stimulate the release of norepinephrine, a small molecule hormone, from the ovary.
Reported in ACS … Read more
By Doug Wendt
The cancer journey is always overwhelming. No human can come away from the experience unscathed. You begin with a symptom here, a sign there, or maybe something appears on a routine checkup or in imaging. Suddenly, the … Read more
The extent to which the BRCA1 promoter is methylated could signal an ovarian tumor’s susceptibility to PARP inhibitor treatment, a new study has found.
PARP inhibitor treatment has been effective in treating some patients with high-grade serous ovarian carcinoma with … Read more
Despite months of aggressive treatment involving surgery and chemotherapy, about 85 percent of women with high-grade wide-spread ovarian cancer will have a recurrence of their disease. This leads to further treatment, but never to a cure. About 15 percent of… Read more
An analysis of the NRG Oncology clinical trial NRG-GY003 suggests that adding ipilimumab, a monoclonal antibody that targets the protein receptor CTLA-4, to a regimen with the checkpoint inhibitor nivolumab could improve the proportion with tumor response and progression-free survival … Read more
By Diane Mapes
Despite its long-standing nickname, ovarian cancer isn’t really a silent killer. There are symptoms; it’s just that they whisper or are commonly mistaken for something else, like aging or irritable bowel syndrome. As a result of this